“…At the highest dose (10.0 mg/kg), however, the WAY 161503-induced changes in open arm exploration and risk-assessment were accompanied by a robust hypolocomotion as indicated by reduction in the absolute number of closed-arm entries. As a whole these results further corroborate previously reported studies showing selective, preferential and non-selective 5-HT 2C agonists to exhibit anxiogeniclike properties and locomotor impairments (Kennett et al 1989;Rodgers et al 1992;Grewal et al 1997;Mora et al 1997;Olivier et al 1998;Setem et al 1999;Bagdy et Repeated EPM exposures are known to reduce or abolish the anxiolytic-like effects of benzodiazepines, a phenomenon known as "one-trail tolerance" or acute tolerance in this test (File, 1990;File, 1993;File, Zangrossi, Viana, & Graeff, 1993;File, Gonzalez, & Gallant, 1999;Frussa-Filho & Ribeiro, 2002;Vargas, Da Cunha, & Andreatini, 2006;Albrechet-Souza, Borelli, & Brandão, 2008). Our present results with the 5-HT 2C agonist WAY 161503 showed that both the first and second EPM exposures were similarly able to detect anxiogenic-like effects.…”